Agenus Announces Appointment of Tom Harrison to Board of Directors
Agenus (NASDAQ: AGEN) has appointed Tom Harrison to its Board of Directors, aiming to leverage his extensive expertise in healthcare advertising, branding, and strategic advising to elevate the company's visibility.
Harrison, former Chairman Emeritus of DAS at Omnicom, led the world's largest marketing services group, expanding its client base to over 5,000 and generating annual revenues of over $6 billion. He also co-founded the successful healthcare agency Harrison & Star.
Currently, Harrison is a Senior Operating Partner at Merida Capital Partners and serves on the boards of AFC Gamma and Acurx Pharmaceuticals.
Agenus believes Harrison's background will be instrumental in enhancing their communication strategies, educating stakeholders about their innovative immunotherapy pipeline, and elevating their reputation within the scientific and medical communities.
Agenus (NASDAQ: AGEN) ha nominato Tom Harrison nel suo Consiglio di Amministrazione, con l’obiettivo di sfruttare la sua vasta esperienza nella pubblicità sanitaria, nel branding e nella consulenza strategica per aumentare la visibilità dell’azienda.
Harrison, ex Presidente Emerito di DAS presso Omnicom, ha diretto il più grande gruppo di servizi di marketing al mondo, ampliando la sua base di clienti a oltre 5.000 e generando ricavi annuali superiori a 6 miliardi di dollari. Ha anche co-fondato la rinomata agenzia sanitaria Harrison & Star.
Attualmente, Harrison è un Partner Operativo Senior presso Merida Capital Partners e fa parte dei consigli di amministrazione di AFC Gamma e Acurx Pharmaceuticals.
Agenus crede che l'esperienza di Harrison sarà fondamentale per migliorare le loro strategie di comunicazione, educare gli stakeholder riguardo al loro innovativo pipeline di immunoterapia e accrescere la loro reputazione all'interno delle comunità scientifiche e mediche.
Agenus (NASDAQ: AGEN) ha nombrado a Tom Harrison en su Junta Directiva, con el objetivo de aprovechar su amplia experiencia en publicidad de salud, branding y asesoría estratégica para aumentar la visibilidad de la empresa.
Harrison, ex Presidente Emérito de DAS en Omnicom, dirigió el grupo de servicios de marketing más grande del mundo, ampliando su base de clientes a más de 5,000 y generando ingresos anuales superiores a 6 mil millones de dólares. También cofundó la exitosa agencia de salud Harrison & Star.
Actualmente, Harrison es un Socio Operativo Sénior en Merida Capital Partners y forma parte de las juntas de AFC Gamma y Acurx Pharmaceuticals.
Agenus cree que la trayectoria de Harrison será fundamental para mejorar sus estrategias de comunicación, educar a los interesados sobre su innovador pipeline de inmunoterapia y elevar su reputación dentro de las comunidades científica y médica.
Agenus (NASDAQ: AGEN)은 Tom Harrison을 이사회에 임명하여 의료 광고, 브랜딩 및 전략적 자문에 대한 그의 풍부한 전문 지식을 활용하여 회사의 가시성을 높이는 것을 목표로 하고 있습니다.
Harrison은 Omnicom의 DAS에서 명예 의장을 역임했으며, 세계 최대의 마케팅 서비스 그룹을 이끌며 고객을 5,000명 이상으로 늘리고 연간 수익을 60억 달러 이상으로 창출했습니다. 그는 또한 성공적인 건강 관리 에이전시인 Harrison & Star를 공동 설립했습니다.
현재 Harrison은 Merida Capital Partners의 수석 운영 파트너이며 AFC Gamma와 Acurx Pharmaceuticals의 이사로 활동하고 있습니다.
Agenus는 Harrison의 배경이 그들의 커뮤니케이션 전략을 향상시키고 이해관계자들에게 혁신적인 면역 요법 파이프라인에 대해 교육하며 과학 및 의료 커뮤니티 내에서의 명성을 높이는 데 중요한 역할을 할 것이라고 믿고 있습니다.
Agenus (NASDAQ: AGEN) a nommé Tom Harrison au sein de son conseil d'administration, visant à tirer parti de son expertise approfondie en matière de publicité dans le secteur de la santé, de branding et de conseil stratégique pour accroître la visibilité de l'entreprise.
Ancien président émérite de DAS chez Omnicom, Harrison a dirigé le plus grand groupe de services marketing au monde, élargissant sa clientèle à plus de 5 000 et générant des revenus annuels de plus de 6 milliards de dollars. Il est également co-fondateur de l'agence de santé Harrison & Star, qui a connu un grand succès.
Actuellement, Harrison est partenaire opérationnel senior chez Merida Capital Partners et siège aux conseils d'administration d'AFC Gamma et d'Acurx Pharmaceuticals.
Agenus est convaincu que l'expérience de Harrison sera essentielle pour améliorer leurs stratégies de communication, éduquer les parties prenantes sur leur pipeline innovant de thérapies immunologiques et rehausser leur réputation au sein des communautés scientifique et médicale.
Agenus (NASDAQ: AGEN) hat Tom Harrison in seinen Vorstand berufen, mit dem Ziel, seine umfangreiche Expertise in der Gesundheitswerbung, im Branding und in der strategischen Beratung zu nutzen, um die Sichtbarkeit des Unternehmens zu erhöhen.
Harrison, ehemaliger Ehrenvorsitzender von DAS bei Omnicom, leitete die größte Marketingdienstleistungsgruppe der Welt, erweiterte deren Kundenstamm auf über 5.000 und erzielte jährliche Einnahmen von über 6 Milliarden Dollar. Zudem war er Mitgründer der erfolgreichen Gesundheitsagentur Harrison & Star.
Derzeit ist Harrison Senior Operating Partner bei Merida Capital Partners und sitzt im Vorstand von AFC Gamma und Acurx Pharmaceuticals.
Agenus ist der Überzeugung, dass Harrisons Erfahrung entscheidend dazu beitragen wird, ihre Kommunikationsstrategien zu verbessern, die Stakeholder über ihr innovatives Immuntherapie-Pipeline aufzuklären und ihren Ruf innerhalb der wissenschaftlichen und medizinischen Gemeinschaften zu stärken.
- Appointment of Tom Harrison to Agenus' Board of Directors.
- Harrison's extensive experience in healthcare advertising and strategic advising.
- Harrison's track record of leading DAS to over $6 billion in annual revenues.
- Potential risks related to changes in board dynamics and continuity.
Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline
Tom Harrison's Background Highlights:
-
Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, branding, and healthcare advertising. Under his leadership, DAS grew to become the largest division within Omnicom Group, generating annual revenues of over
$6 billion -
Experience in Leading Marketing Services Companies: Harrison's tenure at DAS saw the division expand to over 5,000 worldwide clients, accounting for more than
50% of Omnicom's total revenues. He acquired and led a group of companies that became influential in their respective disciplines. - Proven Track Record in Healthcare Advertising: Before joining Omnicom, Harrison co-founded Harrison & Star Business Group, which became the most successful and rapidly growing agency in the healthcare industry. His unique approach fused high science with high creativity, positioning the agency as a leader in the market.
- Senior Operating Partner at Merida Capital Partners: In his current role, Harrison focuses on strategic and operational advising across Merida's portfolio companies, contributing his expertise to the dynamic cannabis industry.
In addition to his role at Merida Capital Partners, Mr. Harrison serves on the boards of AFC Gamma and Acurx Pharmaceuticals.
“We are thrilled to welcome Tom Harrison to our Board of Directors,” said Garo Armen, PhD, Chairman and CEO of Agenus. “Tom’s extensive experience in healthcare advertising and strategic advising, combined with his proven leadership skills, will be invaluable as we continue to advance our mission of harnessing the power of the immune system to bring innovative therapies to patients.”
Educating the World About Agenus and Our Pipeline
As Agenus continues to develop its robust pipeline of novel immunotherapy candidates, the importance of effectively communicating our scientific advancements and therapeutic potential to a global audience cannot be overstated. Tom Harrison’s background in leading large-scale marketing and communications efforts uniquely positions him to drive these initiatives forward.
Harrison's experience in healthcare advertising and branding will be instrumental in elevating Agenus' visibility and reputation within the scientific and medical communities. His ability to convey complex scientific concepts in an accessible and compelling manner will help educate stakeholders, including healthcare providers, patients, investors, and regulatory bodies, about the groundbreaking work being conducted at Agenus.
“Tom’s expertise in strategic communications and his deep understanding of the healthcare landscape will play a critical role in our efforts to educate the world about Agenus’ innovative pipeline,” added Dr. Armen. “His leadership will be crucial as we strive to enhance awareness and understanding of our mission to improve patient outcomes through cutting-edge immunotherapies.”
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808315840/en/
Investors
917-362-1370
investor@agenusbio.com
Media
612-839-6748
communications@agenusbio.com
Source: Agenus Inc.
FAQ
Who has Agenus appointed to its Board of Directors?
What experience does Tom Harrison bring to Agenus?
How might Tom Harrison's appointment impact Agenus' stock (AGEN)?
What were Tom Harrison's notable achievements at DAS?
Why is Tom Harrison's expertise important for Agenus?
